盘龙药业: 董事和高级管理人员所持公司股份及其变动管理规则

General Principles - The rules are established to strengthen the management of shares held by directors and senior management of Shaanxi Panlong Pharmaceutical Group Co., Ltd. and to maintain market order [1] - The rules are based on relevant laws and regulations including the Company Law and Securities Law of the People's Republic of China [1] Share Management - Directors and senior management are prohibited from transferring shares under certain conditions, such as within one year of the company's stock listing or during investigations related to securities violations [3] - The maximum amount of shares that can be transferred by directors and senior management in a year is limited to 25% of their total holdings, with exceptions for certain circumstances [4] - Newly acquired shares can only be transferred at a rate of 25% in the year they are acquired, and any increase in shares due to company actions will proportionally increase the transferable amount [4] Disclosure Requirements - Directors and senior management must report their share transactions to the company and disclose relevant information to the stock exchange within two trading days of any change [12] - A detailed plan must be disclosed prior to any share reduction, including the number of shares, time frame, and reasons for the reduction [5][7] - Any shareholding changes due to court-ordered transactions must be disclosed within two trading days of receiving the execution notice [6] Additional Regulations - Directors and senior management must ensure that their immediate family members and related parties do not engage in insider trading [24] - The rules apply to various scenarios including share increases due to capital increases or stock options [18] - The company is responsible for ensuring the accuracy and timeliness of the reported data [25]